Ohio State University has synthesized DNA topoisomerase II (bacterial) inhibitors reported to be useful for the treatment of Staphylococcus aureus infections.
Nanjing Tian Yin Jian Hua Pharma Tech Co. Ltd. has disclosed receptor-interacting serine/threonine-protein kinase 1 (RIPK1; RIP-1) inhibitors acting as necroptosis inhibitors reported to be useful for the treatment of amyotrophic lateral sclerosis, ulcerative colitis, multiple sclerosis, psoriasis, rheumatoid arthritis and Alzheimer’s disease, among others.
Precision Biosciences Inc. has received pre-IND regulatory feedback from the FDA and ex-U.S. agencies providing alignment and clarity on Precision's final IND/CTA-enabling preclinical plans and clinical strategy for PBGENE-HBV.
Vantai Inc. and Bristol Myers Squibb Co. have entered into a strategic collaboration to discover new molecular glues for therapeutic targets of interest.
Investigators from the Chinese Academy of Medical Sciences & Peking Union Medical College presented data from a study that investigated the regulatory mechanisms of intestinal epithelial cell (IEC) death and intestinal inflammation.
Researchers from Mercer University have presented a middle cerebral artery/ferric chloride (MCA/FeCl3) thromboembolic mouse model of COVID-19-induced stroke and cerebrovascular complications.
Genome sequencing has identified several single-nucleotide polymorphisms (SNPs) tied to osteoporosis, but most of them are located in noncoding regions. Investigators identified a SNP which impacted the YY2-PAPSS2 axis and risk of osteoporosis; the PAPSS2 gene encodes bifunctional 3’-phosphoadenosine 5’-phosphosulfate synthase 2.
Researchers from the Yale University School of Medicine have developed a novel murine model of Gaucher disease type I with the aim to investigate the impact of GBA1 deficiency on hematopoiesis and the immune system, in order to elucidate potential therapeutic targets.
RSS
